VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 15, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F), announced today its skin lightening compounds have shown to have significant antioxidant activity. The study was performed by Biogalenys, a France based company (www.biogalenys.com). Antioxidant testing measures the ability of a compound to inhibit the oxidation of other molecules. Insufficient levels of antioxidants can cause oxidative stress, which produces free radicals that can be toxic to parts of cells, potentially causing diseases. Antioxidants are being investigated for their abilities to prevent diseases.
In the study, the antioxidant potential of compounds TFC-849 and TFC-723 was evaluated using a standard DPPH assay, and their efficiency factors were determined. The antioxidant activity of the compounds was evaluated by determining resultant levels of IC50, a molar ratio showing the concentration of the antioxidant leading to 50% reduction of the initial DPPH concentration. Both of the company's compounds were proven to have free radical scavenging activity.
While both compounds were qualified as antioxidants, TFC-723 showed to be two times more efficient than both natural alpha and beta arbutin. Moreover, the free radical scavenging activity of TFC-723 was slightly higher than that of Ascorbic Acid Glucoside, commonly used in cosmetic products for this purpose.
"In scientific research, our compounds continue to demonstrate superior efficacy and safety and now show the added benefit of proven antioxidant properties," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "This is another exciting breakthrough and again raises the bar of quality in a multi-billion dollar industry," he added.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.